Claims
- 1. The process of Scheme 1, comprising the steps of:(a) combining the compound 3b: with the amino lactone 4: in the presence of an acylating reagent to form the coupled product 6: (b) treating compound 6 with an allyl bromide to give amide 7: (c) reduction of the lactone compound 7 to the corresponding lactol, compound 8: (d) desilylation of compound 8 to compound 9: (e) cyclization of compound 9 to compound 10: (f) reduction of the lactam in compound 10 to the corresponding cyclic aminal which upon exposure to HCN provided the pentacyclic amino nitrile, compound 5:
- 2. The process of Scheme 2, comprising the steps of:(a) conversion of the compound 11: to the mono L-butyldimethylsilyl (TBS) ether, compound 12: (b) etherification with methoxymethyl chloride to yield compound 13: (c) cleaving the N-allyloxycarbonyl and O-allyl groups in 13 gives the secondary amine, compound 14: (d) N-methylation of compound 14 affords compound 15: (e) C-methylation of compound 15 affords compound 16: (f) acetylation of phenol 16 affords the corresponding acetate, compound 17: (g) desilylation of compound 17 yields the primary alcohol, compound 18: (h) Mitsunobu displacement of the primary hydroxyl of 18, yields the phthalimide, compound 19: (i) acid-catalyzed cleavage of the methoxymethyl ether in compound 19, generates compound 2-phthalascidin:
- 3. The synthetic intermediate of Scheme 1-compound 6:
- 4. The synthetic intermediate of Scheme 1-compound 7:
- 5. The synthetic intermediate of Scheme 1-compound 8:
- 6. The synthetic intermediate of Scheme 1-compound 9:
- 7. The synthetic intermediate of Scheme 1-compound 10:
- 8. The synthetic intermediate of Scheme 2-compound 12:
- 9. The synthetic intermediate of Scheme 2-compound 13:
- 10. The synthetic intermediate of Scheme 2-compound 14:
- 11. The synthetic intermediate of Scheme 2-compound 15:
- 12. The synthetic intermediate of Scheme 2-compound 16:
- 13. The synthetic intermediate of Scheme 2-compound 17:
- 14. The synthetic intermediate of Scheme 2-compound 18:
- 15. The synthetic intermediate of Scheme 2-compound 19:
PRIORITY CLAIM AND CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of PCT Application No. PCT/US01/04376 filed Feb. 9, 2001, which was published in English on Aug. 16, 2001 as WO 01/58905. The PCT Application claims priority from U.S. Provisional Application Ser. No. 60/181,795, filed 11 Feb. 2000. The disclosures of these applications are hereby incorporated herein by reference.
STATEMENT OF GOVERNMENT SUPPORT
This invention was supported by funding from the Government of the United States of America, by virtue of Grant No. GM34167 awarded by the National Institutes of Health. Thus, the Governmant may have certain rights in this invention.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5721362 |
Corey et al. |
Feb 1998 |
A |
6124292 |
Corey |
Sep 2000 |
A |
Non-Patent Literature Citations (4)
Entry |
Cuevas, et al. Synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 from Cyanosafracin B. Organic Letters. (Jul. 19, 2000), vol. 2, No. 16, pp. 2545-2548. |
Martinez, et al. A New, More Efficient, and Effective Process For the Synthesis of a Key Pentacyclic Intermediate for Production of Ecteinascidin and Phthalascidin Antitumor Agents. Organic Letters. (Mar. 15, 2000), vol. 2, No. 7, pp. 993-996. |
Corey, et al. Enantioselective Total Synthesis of Ecteinascidin 743. J. Am. Chem. Soc. 1996, 118, 9202-3. |
Greene, et al. Protective Groups in Organic Synthesis. New York: John Wiley & Sons, Inc. 1991, second edition, pp. 77 and 83. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/181795 |
Feb 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US01/04376 |
Feb 2001 |
US |
Child |
10/213711 |
|
US |